Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025
VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for April 9, 2025, at 10:00 AM ET, focusing on their Nu.Q® Cancer platform. Key executives including Chief Commercial Officer Gael Forterre, Chief Medical Officer Dr. Andrew Retter, and Chief Scientific Officer Dr. Jake Micallef will present.
The event will showcase findings from large independent studies supporting their Nu.Q® platform in cancer detection. Notably, recent research undergoing peer review indicates that the Nu.Q® Cancer test successfully detected multiple common cancers (lung, breast, prostate, colon, and liver) with an overall AUC of 86% and low false positive rates.
The company is targeting two significant market opportunities:
- The lung cancer market (screening, prognostication, and minimal residual disease) estimated at $4 billion
- The liquid biopsy market for multi-cancer early detection in the U.S., valued at approximately $20 billion
VolitionRx (NYSE: VNRX) ha annunciato un evento virtuale per gli investitori programmato per il 9 aprile 2025, alle 10:00 AM ET, incentrato sulla loro piattaforma Nu.Q® Cancer. Esecutivi chiave come il Chief Commercial Officer Gael Forterre, il Chief Medical Officer Dr. Andrew Retter e il Chief Scientific Officer Dr. Jake Micallef presenteranno.
L'evento mostrerà i risultati di ampi studi indipendenti a sostegno della loro piattaforma Nu.Q® nella rilevazione del cancro. In particolare, recenti ricerche in fase di revisione paritaria indicano che il test Nu.Q® Cancer ha rilevato con successo diversi tumori comuni (polmoni, seno, prostata, colon e fegato) con un AUC complessivo dell'86% e bassi tassi di falsi positivi.
L'azienda sta puntando a due significative opportunità di mercato:
- Il mercato del cancro ai polmoni (screening, prognosi e malattia residua minima) stimato in 4 miliardi di dollari
- Il mercato della biopsia liquida per la rilevazione precoce di più tumori negli Stati Uniti, valutato a circa 20 miliardi di dollari
VolitionRx (NYSE: VNRX) ha anunciado un evento virtual para inversores programado para el 9 de abril de 2025, a las 10:00 AM ET, centrado en su plataforma Nu.Q® Cancer. Ejecutivos clave como el Director Comercial Gael Forterre, el Director Médico Dr. Andrew Retter y el Director Científico Dr. Jake Micallef presentarán.
El evento mostrará hallazgos de grandes estudios independientes que respaldan su plataforma Nu.Q® en la detección de cáncer. En particular, investigaciones recientes en revisión por pares indican que la prueba Nu.Q® Cancer detectó con éxito múltiples cánceres comunes (pulmón, mama, próstata, colon y hígado) con un AUC general del 86% y bajas tasas de falsos positivos.
La empresa está apuntando a dos oportunidades de mercado significativas:
- El mercado del cáncer de pulmón (detección, pronóstico y enfermedad residual mínima) estimado en 4 mil millones de dólares
- El mercado de biopsia líquida para la detección temprana de múltiples cánceres en EE. UU., valorado en aproximadamente 20 mil millones de dólares
VolitionRx (NYSE: VNRX)는 2025년 4월 9일 오전 10시 ET에 예정된 가상 투자자 이벤트를 발표하며, 이 이벤트는 그들의 Nu.Q® 암 플랫폼에 초점을 맞추고 있습니다. 주요 경영진인 상업 담당 최고 책임자 Gael Forterre, 의학 담당 최고 책임자 Dr. Andrew Retter, 과학 담당 최고 책임자 Dr. Jake Micallef가 발표할 예정입니다.
이번 이벤트는 암 검출을 지원하는 대규모 독립 연구 결과를 선보일 것입니다. 특히, 최근 동료 검토를 받고 있는 연구에 따르면 Nu.Q® Cancer 테스트는 여러 일반 암(폐, 유방, 전립선, 대장 및 간)을 성공적으로 감지했으며, 전체 AUC는 86%이고 낮은 거짓 양성률을 기록했습니다.
회사는 두 가지 주요 시장 기회를 목표로 하고 있습니다:
- 폐암 시장(검진, 예후 및 최소 잔여 질병)으로 추정되는 40억 달러
- 미국 내 다중 암 조기 발견을 위한 액체 생검 시장, 약 200억 달러로 평가됨
VolitionRx (NYSE: VNRX) a annoncé un événement virtuel pour investisseurs prévu le 9 avril 2025 à 10h00 ET, axé sur leur plateforme Nu.Q® Cancer. Des dirigeants clés, dont le directeur commercial Gael Forterre, le directeur médical Dr. Andrew Retter et le directeur scientifique Dr. Jake Micallef, présenteront.
L'événement mettra en avant des résultats d'importantes études indépendantes soutenant leur plateforme Nu.Q® dans la détection du cancer. Notamment, des recherches récentes en cours de révision par des pairs indiquent que le test Nu.Q® Cancer a réussi à détecter plusieurs cancers courants (poumon, sein, prostate, côlon et foie) avec une AUC globale de 86 % et de faibles taux de faux positifs.
L'entreprise vise deux opportunités de marché significatives :
- Le marché du cancer du poumon (dépistage, pronostic et maladie résiduelle minimale) estimé à 4 milliards de dollars
- Le marché de la biopsie liquide pour la détection précoce de plusieurs cancers aux États-Unis, évalué à environ 20 milliards de dollars
VolitionRx (NYSE: VNRX) hat eine virtuelle Investorenveranstaltung für den 9. April 2025 um 10:00 Uhr ET angekündigt, die sich auf ihre Nu.Q® Cancer-Plattform konzentriert. Wichtige Führungskräfte, darunter der Chief Commercial Officer Gael Forterre, der Chief Medical Officer Dr. Andrew Retter und der Chief Scientific Officer Dr. Jake Micallef, werden präsentieren.
Die Veranstaltung wird Ergebnisse aus großen unabhängigen Studien vorstellen, die ihre Nu.Q®-Plattform zur Krebsdetektion unterstützen. Besonders hervorzuheben ist, dass aktuelle, sich im Peer-Review befindliche Forschungsergebnisse zeigen, dass der Nu.Q® Cancer-Test erfolgreich mehrere häufige Krebsarten (Lunge, Brust, Prostata, Dickdarm und Leber) mit einer Gesamt-AUC von 86 % und niedrigen falsch-positiven Raten erkannt hat.
Das Unternehmen zielt auf zwei bedeutende Marktchancen ab:
- Den Markt für Lungenkrebs (Screening, Prognose und minimale Restkrankheit), der auf 4 Milliarden Dollar geschätzt wird
- Den Markt für Flüssigbiopsien zur frühzeitigen Erkennung von mehreren Krebsarten in den USA, der auf etwa 20 Milliarden Dollar geschätzt wird
- None.
- None.
This webinar will provide an overview following the completion of a number of large independent studies supporting the value of our Nu.Q® platform in cancer.
Mr. Forterre will provide an update on Volition's progress to commercialization through both licensing and direct and indirect sales.
Dr. Retter will focus on the potential role of Volition's Nu.Q® assays in the management of lung cancer: from screening to aiding treatment selection at diagnosis and monitoring treatment response, minimal residual disease and disease progression.
The Total Annual Accessible Market for lung cancer (screening, prognostication and identification of minimal residual disease) is estimated to be approximately
Dr Micallef will discuss findings published in a paper currently undergoing peer review and accessible on MedRXIV, which reported that the Nu.Q® Cancer test detected common cancer diseases, including cancers of the lung, breast, prostate, colon and liver (overall AUC=
We are excited to publish this further validation of our Nu.Q® platform; it represents a potential opportunity to disrupt the
A live question and answer session will follow the formal presentations.
1.Data on file, Volition Total Addressable Market model.
About Gael Forterre
Gael Forterre is the Chief Commercial Officer of Volition, joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of assays developed using the Nu.Q® platform. Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Pathify. He is currently the non-executive chairman of Vahau.
Gael started his career as a hedge fund analyst in
About Dr. Andrew Retter
Andrew Retter, BSc (Hons), MBBS, FRCP, FRCPath (Haem), DICM is Consultant in Critical Care, ECMO & Thrombosis and also the Clinical Lead for Critical Care at one of the
About Dr. Jake Micallef
Jake Micallef PhD, MBA is the Chief Scientific Officer and one of the founding scientists of Volition. He is an experienced scientist with expertise in research and development in diagnostics, both commercially and for the
Jake received both his BSc in Biology and Chemistry and Ph.D. in Physical Chemistry from King's College London. In addition, he received his MSc in Chemical Pathology from
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:https://www.prnewswire.com/news-releases/volition-to-host-virtual-investor-event-on-nuq-cancer-a-look-to-the-future-of-cancer-diagnostics-on-april-9-2025-302413141.html
SOURCE VolitionRx Limited